Updated Jul 16, 2026
Lorrain Daniel S. has filed 4 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $1.16M.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-10 | CTNM | Contineum Therapeutics, Inc. | S — Open-market sale | 25 | $16.00 | $400 |
| 2026-07-10 | CTNM | Contineum Therapeutics, Inc. | M — Option exercise | 25 | $1.01 | $25 |
| 2026-07-10 | CTNM | Contineum Therapeutics, Inc. | S — Open-market sale | 1.0K | $16.00 | $16K |
| 2026-07-10 | CTNM | Contineum Therapeutics, Inc. | M — Option exercise | 1.0K | $1.01 | $1K |
| 2026-07-02 | CTNM | Contineum Therapeutics, Inc. | S — Open-market sale | 2.5K | $16.24 | $41K |
| 2026-07-02 | CTNM | Contineum Therapeutics, Inc. | S — Open-market sale | 5.9K | $15.67 | $92K |
| 2026-07-02 | CTNM | Contineum Therapeutics, Inc. | M — Option exercise | 4.2K | $1.01 | $4K |
| 2026-07-02 | CTNM | Contineum Therapeutics, Inc. | S — Open-market sale | 28.8K | $16.04 | $462K |
| 2026-07-02 | CTNM | Contineum Therapeutics, Inc. | M — Option exercise | 28.8K | $1.01 | $29K |
| 2026-06-01 | CTNM | Contineum Therapeutics, Inc. | S — Open-market sale | 4.2K | $13.16 | $55K |
| 2026-05-01 | CTNM | Contineum Therapeutics, Inc. | S — Open-market sale | 300 | $13.84 | $4K |
| 2026-05-01 | CTNM | Contineum Therapeutics, Inc. | S — Open-market sale | 3.9K | $13.06 | $51K |
| 2026-04-06 | CTNM | Contineum Therapeutics, Inc. | S — Open-market sale [10b5-1] | 4.2K | $13.43 | $56K |
| 2026-03-02 | CTNM | Contineum Therapeutics, Inc. | S — Open-market sale [10b5-1] | 4.2K | $15.01 | $63K |
| 2026-02-26 | CTNM | Contineum Therapeutics, Inc. | S — Open-market sale [10b5-1] | 3.8K | $16.01 | $61K |
| 2026-02-26 | CTNM | Contineum Therapeutics, Inc. | M — Option exercise [10b5-1] | 3.8K | $1.01 | $4K |
| 2026-02-26 | CTNM | Contineum Therapeutics, Inc. | S — Open-market sale [10b5-1] | 4.3K | $16.03 | $69K |
| 2026-02-26 | CTNM | Contineum Therapeutics, Inc. | M — Option exercise [10b5-1] | 4.3K | $1.01 | $4K |
| 2026-02-20 | CTNM | Contineum Therapeutics, Inc. | S — Open-market sale [10b5-1] | 100 | $16.00 | $2K |
| 2026-02-20 | CTNM | Contineum Therapeutics, Inc. | M — Option exercise [10b5-1] | 100 | $1.01 | $101 |
Lorrain Daniel S. is a corporate insider — currently tracked as Chief Scientific Officer of Contineum Therapeutics, Inc. (CTNM). InsiderAlpha tracks every SEC Form 4 filing in real time.
4 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 19 open-market sales ($1.16M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Lorrain Daniel S. profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.